As part of the acquisition, CentralReach will remain independent, preserving its team, brands, products and mission.

Roper Technologies (ROP) has reached a definitive agreement to acquire CentralReach from Insight Partners for a net purchase ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides ...

CentralReach, a leader in autism and IDD care software for applied behavior analysis (ABA), multidisciplinary therapy, and special education, today announced that it has entered into a definitive ...

1. Patients randomised 1:1 in AIPAC-003 Phase II to receive 30mg or 90mg dosing of eft in combination with paclitaxel to ...

Roper Technologies (ROP) said Monday that it agreed to acquire CentralReach, an autism therapy software provider, in a $1.65 billion deal that it expects to close within the next two months. Roper is ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, ...

In a lighthearted interview with Cadena Cope, Barcelona defender Koubasi shared an amusing anecdote about his sister, Irina, a final-year physiotherapy student. Despite her professional training, ...

Being a cycle breaker can feel like both a burden and a gift. Here are some signs you may be breaking the cycle of trauma.

CentralReach is a leading provider of cloud-native software enabling the workflow and administration of Applied Behavior Analysis (“ABA”) therapy. Over 200,000 professionals utilize CentralReach’s ...

Roper Technologies (ROP) acquires CentralReach for $1.65B, enhancing its software portfolio with high-growth solutions.